Segmentation, Major Trends, and Competitive Analysis of the Biologics Contract Development Market

The biologics contract development sector is poised for significant expansion as demand for sophisticated biologic therapies rises. Innovations and strategic investments are shaping this market's promising outlook, with many companies enhancing their capabilities to meet growing industry needs. Below, we explore the market's size projections, leading players, key trends, and segmentation to provide a comprehensive view of this evolving field.

Market Size Outlook and Growth Prospects in the Biologics Contract Development Market
The biologics contract development market is projected to experience substantial growth in the coming years, reaching a market value of $14.46 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 11.0%. Driving this growth are factors such as the increasing necessity for rapid biologics scale-up, rising investments in advanced mammalian cell platforms, the broadening oncology biologics pipelines, and a growing emphasis on flexible manufacturing capacities. Additionally, the adoption of digital bioprocess optimization techniques is further accelerating market development. Key evolving trends include the increasing outsourcing of biologics process development, demand for scalable cell line development, widespread use of single-use bioprocessing systems, expansion of integrated CDMO service models, and a stronger focus on speed-to-clinic development.

Download a free sample of the biologics contract development market report:
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Drivers Boosting the Biologics Contract Development Market Growth
The surge in demand for faster scale-up of biologic products is a critical growth driver, as pharmaceutical companies seek to accelerate time-to-market for innovative therapies. This urgency is complemented by rising investments in mammalian cell platforms, which enhance the efficiency and yield of biologic production processes.
Another important factor is the expanding pipeline of oncology biologics, which fuels the need for flexible and scalable manufacturing solutions. Moreover, the growing adoption of digital bioprocess optimization and single-use systems enables manufacturers to increase production agility and reduce contamination risks, further propelling market momentum.

Leading Players Shaping the Biologics Contract Development Industry
Several key companies are at the forefront of the biologics contract development market, including WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc., LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, and Yposkesi.
In a significant move in October 2024, Switzerland-based Lonza acquired Genentech's large-scale biologics manufacturing facility in Vacaville, California, from Roche for $1.2 billion. This acquisition aims to strengthen Lonza's footprint in the U.S. biologics market, expand its large-scale mammalian production capabilities, and enhance end-to-end CDMO services offered to external clients. The Genentech Vacaville site specializes in clinical and commercial-scale biologics manufacturing, including fill and finish services.

The biologics contract development sector is poised for significant expansion as demand for sophisticated biologic therapies rises. Innovations and strategic investments are shaping this market's promising outlook, with many companies enhancing their capabilities to meet growing industry needs. Below, we explore the market's size projections, leading players, key trends, and segmentation to provide a comprehensive view of this evolving field.

Market Size Outlook and Growth Prospects in the Biologics Contract Development Market
The biologics contract development market is projected to experience substantial growth in the coming years, reaching a market value of $14.46 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 11.0%. Driving this growth are factors such as the increasing necessity for rapid biologics scale-up, rising investments in advanced mammalian cell platforms, the broadening oncology biologics pipelines, and a growing emphasis on flexible manufacturing capacities. Additionally, the adoption of digital bioprocess optimization techniques is further accelerating market development. Key evolving trends include the increasing outsourcing of biologics process development, demand for scalable cell line development, widespread use of single-use bioprocessing systems, expansion of integrated CDMO service models, and a stronger focus on speed-to-clinic development.

Download a free sample of the biologics contract development market report:
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Drivers Boosting the Biologics Contract Development Market Growth
The surge in demand for faster scale-up of biologic products is a critical growth driver, as pharmaceutical companies seek to accelerate time-to-market for innovative therapies. This urgency is complemented by rising investments in mammalian cell platforms, which enhance the efficiency and yield of biologic production processes.
Another important factor is the expanding pipeline of oncology biologics, which fuels the need for flexible and scalable manufacturing solutions. Moreover, the growing adoption of digital bioprocess optimization and single-use systems enables manufacturers to increase production agility and reduce contamination risks, further propelling market momentum.

Leading Players Shaping the Biologics Contract Development Industry
Several key companies are at the forefront of the biologics contract development market, including WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc., LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, and Yposkesi.
In a significant move in October 2024, Switzerland-based Lonza acquired Genentech's large-scale biologics manufacturing facility in Vacaville, California, from Roche for $1.2 billion. This acquisition aims to strengthen Lonza's footprint in the U.S. biologics market, expand its large-scale mammalian production capabilities, and enhance end-to-end CDMO services offered to external clients. The Genentech Vacaville site specializes in clinical and commercial-scale biologics manufacturing, including fill and finish services.

Emerging Trends Positively Impacting the Biologics Contract Development Market
Companies in this market are focusing heavily on developing advanced products such as 3D cell culture plates to better meet research and development needs. These products provide physiologically relevant models that support more effective experimentation and drug development.
For example, in May 2024, the US-based biotechnology firm TheWell Bioscience introduced VitroPrime Spread-Attach Plates. Designed for both hydrogel-based 3D and 2D cell cultures, these plates improve hydrogel spreading and cell attachment, ensuring uniform gel distribution and minimizing edge effects. This innovation promotes rapid cell growth, making it ideal for high-throughput research applications.

Detailed Segmentation of the Biologics Contract Development Market
This market is segmented into three primary categories:
1) By Source:
- Microbial
- Mammalian
- Other Sources
2) By Indication:
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Other Indications
3) By Product Service:
- Cell Line Development
- Process Development
- Other Product Services

The microbial segment is further divided into bacterial, yeast, and fungal sources. Mammalian sources include Chinese Hamster ovary* (CHO) cells, Human Embryonic Kidney (HEK) cells, and Hybridoma cells. Other sources cover plant-based systems, insect cell systems, and algal sources.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.